The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10914 malaria professionals are enjoying the free benefits of MalariaWorld today

circumsporozoite protein

NOT Open Access | Epitope-Specific Antibody Responses to a Plasmodium falciparum Subunit Vaccine Target in a Malaria-Endemic Population

June 9, 2021 - 07:28 -- NOT Open Access
Friedman-Klabanoff DJ, Travassos MA, Berry AA, et al.
J Infect Dis. 2021 Jun 4;223(11):1943-1947

Circumsporozoite protein (CSP) coats the Plasmodium falciparum sporozoite surface and is a major malaria subunit vaccine target. We measured epitope-specific reactivity to field-derived CSP haplotypes in serum samples from Malian adults and children on a custom peptide microarray. Compared to children, adults showed greater antibody responses and responses to more variants in regions proximal to and within the central repeat region.

NOT open Access | Partial protection against P. vivax infection diminishes hypnozoite burden and blood-stage relapses

May 19, 2021 - 13:32 -- NOT Open Access
Schäfer C, Dambrauskas N, Sather DN, et al.
Cell Host Microbe. 2021 May 12;29(5):752-756.e4

Latent forms of Plasmodium vivax, called hypnozoites, cause malaria relapses from the liver into the bloodstream and are a major obstacle to malaria eradication. To experimentally assess the impact of a partially protective pre-erythrocytic vaccine on reducing Plasmodium vivax relapses, we developed a liver-humanized mouse model that allows monitoring of relapses directly in the blood. We passively infused these mice with a suboptimal dose of an antibody that targets the circumsporozoite protein prior to challenge with P. vivax sporozoites.

Malaria and Cancer: a critical review on the established associations and new perspectives

May 19, 2021 - 13:28 -- Open Access
Ellis T, Eze E, Raimi-Abraham BT
Infect Agent Cancer. 2021 May 13;16(1):33

Cancer and malaria both have high incidence rates and are leading causes of mortality worldwide, especially in low and middle-income countries with reduced access to the quality healthcare. The objective of this critical review was to summarize key associations and new perspectives between the two diseases as is reported in existing literature.

A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development

April 6, 2021 - 14:24 -- Open Access
Atcheson E, Hill AVS, Reyes-Sandoval A
NPJ Vaccines. 2021 Apr 1;6(1):46

Malaria continues to be a pressing global health issue, causing nearly half a million deaths per year. An effective malaria vaccine could radically improve our ability to control and eliminate this pathogen. The most advanced malaria vaccine, RTS,S, confers only 30% protective efficacy under field conditions, and hence the search continues for improved vaccines.

Mechanisms and targets of Fcgamma-receptor mediated immunity to malaria sporozoites

March 23, 2021 - 14:49 -- Open Access
Feng G, Wines BD, Beeson JG, et al.
Nat Commun. 2021 Mar 19;12(1):1742

A highly protective vaccine will greatly facilitate achieving and sustaining malaria elimination. Understanding mechanisms of antibody-mediated immunity is crucial for developing vaccines with high efficacy. Here, we identify key roles in humoral immunity for Fcγ-receptor (FcγR) interactions and opsonic phagocytosis of sporozoites. We identify a major role for neutrophils in mediating phagocytic clearance of sporozoites in peripheral blood, whereas monocytes contribute a minor role.

Fluorescent tagging of Plasmodium circumsporozoite protein allows imaging of sporozoite formation but blocks egress from oocysts

February 23, 2021 - 13:06 -- Open Access
Singer M, Frischknecht F
Cell Microbiol. 2021 Feb 18:e13321

The circumsporozoite protein, CSP is the major surface protein of Plasmodium sporozoites, the form of malaria parasites transmitted by mosquitoes. CSP is involved in sporozoite formation within and egress from oocysts, entry into mosquito salivary glands and mammalian liver as well as migration in the skin. Yet, how CSP facilitates sporozoite formation, oocyst egress and hepatocyte specific invasion is still not fully understood.

An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein

January 27, 2021 - 10:04 -- Open Access
Jelínková L, Jhun H, Eaton A, Petrovsky N, Zavala F, Chackerian B
NPJ Vaccines. 2021 Jan 21;6(1):13

A malaria vaccine that elicits long-lasting protection and is suitable for use in endemic areas remains urgently needed. Here, we assessed the immunogenicity and prophylactic efficacy of a vaccine targeting a recently described epitope on the major surface antigen on Plasmodium falciparum sporozoites, circumsporozoite protein (CSP). Using a virus-like particle (VLP)-based vaccine platform technology, we developed a vaccine that targets the junctional region between the N-terminal and central repeat regions of CSP. This region is recognized by monoclonal antibodies, including mAb CIS43, that have been shown to potently prevent liver invasion in animal models. We show that CIS43 VLPs elicit high-titer and long-lived anti-CSP antibody responses in mice and is immunogenic in non-human primates.

Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention

December 23, 2020 - 08:35 -- Open Access
Kielau Kisalu N, Da Silva Pereira L, Ernste KJ, Flores-Garcia Y, Idris AH, Asokan M, Dillon M, MacDonald S, Shi W, Chen X, Pegu A, Schön A, Zavala F, Balazs AB, Francica JR, Seder RA
JCI Insight. 2020 Dec 17:143958

CIS43 is a potent neutralizing human monoclonal antibody (mAb) that targets a highly conserved 'junctional' epitope in the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). Enhancing the durability of CIS43 in vivo will be important for clinical translation. Here, two approaches were used to improve the durability of CIS43 in vivo while maintaining potent neutralization.

Structural ordering of the Plasmodium berghei circumsporozoite protein repeats by inhibitory antibody 3D11

December 3, 2020 - 12:17 -- Open Access
Kucharska I, Thai E, Srivastava A, Rubinstein JL, Pomès R, Julien JP
Elife. 2020 Nov 30;9:e59018

Plasmodium sporozoites express circumsporozoite protein (CSP) on their surface, an essential protein that contains central repeating motifs. Antibodies targeting this region can neutralize infection, and the partial efficacy of RTS,S/AS01 - the leading malaria vaccine against P. falciparum (Pf) - has been associated with the humoral response against the repeats.

Population genetic analysis of the Plasmodium falciparum circumsporozoite protein in two distinct ecological regions in Ghana

December 2, 2020 - 07:45 -- Open Access
Elikplim A. Amegashie, Lucas Amenga-Etego, Courage Adobor, Peter Ogoti, Kevin Mbogo, Alfred Amambua-Ngwa and Anita Ghansah
Malaria Journal 2020 19:437, 27 November 2020

Extensive genetic diversity in the Plasmodium falciparum circumsporozoite protein (PfCSP) is a major contributing factor to the moderate efficacy of the RTS,S/AS01 vaccine. The transmission intensity and rates of recombination within and between populations influence the extent of its genetic diversity. Understanding the extent and dynamics of PfCSP genetic diversity in different transmission settings will help to interpret the results of current RTS,S efficacy and Phase IV implementation trials conducted within and between populations in malaria-endemic areas such as Ghana.


Subscribe to RSS - circumsporozoite protein